TEXT

Tamoxifen and exemestane trial.

Disease site: Breast cancer

Treatment modality: Hormone therapy

Status: In active follow-up

Trial details

A phase III trial evaluating the role of exemestane plus GnRH analogue as adjuvant therapy for premenopausal women with endocrine responsive breast cancer.

Patients were randomised to one of two treatment arms:

• Tamoxifen plus Triptorelin
• Exemestane plus Triptorelin

The aim of the trial is to evaluate the worth of ovarian function suppression (achieved by long-term use of Triptorelin) plus exemestane compared with Triptorelin plus tamoxifen, in premenopausal women with steroid hormone receptor positive early invasive breast cancer. The trial will recruit 1,845 patients.

TEXT is one of three complementary trials (the STP Trials) coordinated by the International Breast Cancer Study Group (IBCSG). These trials opened to recruitment internationally on the 4th August 2003 and TEXT closed to recruitment in March 2011.

UK Chief Investigator: Dr H. Earl, University of Cambridge.

UK trial management contact: Agnieszka Yongue, [email protected]

Sponsor: International Breast Cancer Study Group (IBCSG) Berne, Switzerland

Funding: Pfizer

Further information

Further information on the TEXT trial may be found on the IBCSG TEXT trial webpage.